The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | The value of fedratinib for the treatment of patients with MF in the second-line setting
In this video, Francesco Passamonti, MD, University of Milan, Milan, Italy, comments on the value of fedratinib for the treatment of patients with myelofibrosis (MF) in the second-line setting. Prof. Passamonti highlights fedratinib’s therapeutic potential, particularly for patients with significant spleen enlargement or symptomatology who are resistant to ruxolitinib or momelotinib. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
